Prognostic Value of Modified Model for End-Stage Liver Disease Score in Patients Undergoing Isolated Tricuspid Valve Replacement

Xu, Hongjie; Wang, He; Chen, Shisong; Chen, Qian; Xu, Tianyu; Xu, Zhiyun; Sun, Yinghao

doi:10.3389/fcvm.2022.932142

Cited by 2 publications

(2 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Preoperative assessment included calculating EuroScore II risk, Tri-Score band, and MELD Score regarding the patient's age, clinical symptoms of right heart failure, ejection fraction, daily Furosemide intake, and major laboratory findings. Estimated and predicted in-hospital mortality and morbidity along with 3-month predicted mortality were taken into consideration [34][35][36].…”

Section: Preoperative Assessment and Indication For Surgerymentioning

confidence: 99%

Contemporary Approach with Mitral Valve Allograft in the Treatment of Tricuspid Valve Pathology

Nuzhdin¹,

Комаров²,

Bolsunovsky³

2024

Biomedical Engineering

View full text Add to dashboard Cite

Symptomatic tricuspid valve diseases are associated with a high risk of heart failure and poor prognosis. The current valve substitutes still carry the risk of associated complications. Allografts have been considered a valuable surgical option for decades since the first reports were introduced. The challenging surgical technique along with controversial results and homograft shortage discourage surgical society from wider use of allografts in tricuspid surgery. The largest world surgical experience with mitral allograft in the treatment of tricuspid valve disease is described in the study. A total of 20 patients underwent tricuspid valve replacement by mitral homograft in two clinics from October 2021 to February 2023. Surgical technique and initial results are presented in the chapter. There was no early mortality, postoperative bleeding, myocardium infarction, stroke, or sternal wound infection. Two patients needed permanent pacemaker implantation after redoing surgery before discharge. In the follow-up period, two patients suffered from a relapse of infective endocarditis in 3 and 6 months postoperatively with moderate homograft dysfunction, none of them underwent reintervention. There was no late mortality or permanent pacemaker implantation in the follow-up period. Satisfactory clinical and hemodynamic results, reproduceable technique and accessibility make homografts plausible valve substitutes in tricuspid surgery.

show abstract

Section: Preoperative Assessment and Indication For Surgerymentioning

confidence: 99%

Contemporary Approach with Mitral Valve Allograft in the Treatment of Tricuspid Valve Pathology

Nuzhdin¹,

Комаров²,

Bolsunovsky³

2024

Biomedical Engineering

View full text Add to dashboard Cite

show abstract

“…The value of the abovementioned models for iTR-LSVS is still unclear. A thorough preoperative assessment is necessary for each patient, and a specific risk scoring model for iTR-LSVS should be built [ 47 , 48 ].…”

Section: Preoperative Evaluationmentioning

confidence: 99%

2022 CMICS Expert Consensus on the Management of Isolated Tricuspid Regurgitation after Left-Sided Valve Surgery

Chen,

Cheng,

Dong

et al. 2023

Rev. Cardiovasc. Med.

View full text Add to dashboard Cite

Tricuspid regurgitation (TR) may occur late after left-sided valve surgery (LSVS). Isolated tricuspid regurgitation after left-sided valve surgery (iTR-LSVS) refers to isolated TR without significant lesions in the mitral and/or aortic position late after mitral and/or aortic replacement or repair. Severe TR has a negative impact on long-term prognosis and requires surgical or transcatheter treatment. However, there is no clear recommendation on when and how intervention should be performed for patients with iTR-LSVS in the current guidelines for the management of valvular heart disease. The historically high operative mortality may be reduced by current minimally invasive techniques and transcatheter therapy. To further understand iTR-LSVS, standardize the treatment, improve the prognosis, and promote the collaboration, the Chinese Minimally Invasive Cardiovascular Surgery Committee (CMICS) wrote this expert consensus on the management of iTR-LSVS from the aspects of etiology, preoperative evaluation, indications for intervention, surgical treatment, transcatheter therapy, and postoperative management.

show abstract

Prognostic Value of Modified Model for End-Stage Liver Disease Score in Patients Undergoing Isolated Tricuspid Valve Replacement

Cited by 2 publications

References 29 publications

Contemporary Approach with Mitral Valve Allograft in the Treatment of Tricuspid Valve Pathology

Contemporary Approach with Mitral Valve Allograft in the Treatment of Tricuspid Valve Pathology

2022 CMICS Expert Consensus on the Management of Isolated Tricuspid Regurgitation after Left-Sided Valve Surgery

Contact Info

Product

Resources

About